Please login to the form below

CABOSUN trial of cabozantinib – could it change how we treat frontline renal-cell carcinoma?

In the CABOSUN trial, cabozantinib was compared to sunitinib in treatment naive poor and intermediate risk renal-cell carcinoma (RCC) patients.


Summary/transcript

In the CABOSUN trial, cabozantinib was compared to sunitinib in treatment naive poor and intermediate risk renal-cell carcinoma (RCC) patients.

The primary endpoint was PFS and the researchers observed a PFS benefit that they think is “clinically relevant and statistically significant,” as Dr Toni Choueiri of the Dana-Farber Cancer Institute highlights. Further, there was a 31% decrease in risk of progression of death. Also, the secondary endpoint, response rate, was higher and more significant with cabozantinib. Dr Choueiri, who presented the results at ESMO 2016, explains, they also had an early look at overall survival (OS), which is not significant yet but trending in the right direction.

The side effects were similar in both arms and in our interview, Dr Choueiri poses the question if cabozantinib could become the next first-line option after sunitinib, which was the standard and most used first-line agent for ten years. He believes that cabozantinib could become the next first-line option and therefore “it is very possible that this study will change how we treat frontline renal cell cancer”.

If you would like to discover how we can leverage our network of relationships and understanding of the oncology landscape and stakeholders, to shape content and amplify messages across relevant audiences, channels and communities please contact either Stephen Dunn or Charlie Grieve on 020 7291 5070, we’d be delighted to hear from you.






17th November 2016

Share

Tags

Company Details

Brandcast Health

+44 (0)20 7291 5070

Contact Website

Address:
16-17 Little Portland Street
London
W1W 8BP

Latest content on this profile

Day 2 Round-up from the Giant Health Event
Robin gives a quick overview of day 2 of the Giant Health Event.
Brandcast Health
Why patient education is important in oncology
We talked to Dr Bettina Ryll of Melanoma Patient Network Europe about changes in melanoma treatment and how the added complexity of new treatments has changed how patients need to be informed.
Brandcast Health
CABOSUN trial of cabozantinib – could it change how we treat frontline renal-cell carcinoma?
In the CABOSUN trial, cabozantinib was compared to sunitinib in treatment naive poor and intermediate risk renal-cell carcinoma (RCC) patients.
Brandcast Health
No surprises: results from the ENGOT-OV16/NOVA trial of niraparib in ovarian cancer
The ENGOT-OV16/NOVA trial of niraparib was a randomized, double-blinded placebo study with women with relapsed platinum-sensitive high-grade ovarian cancer.
Brandcast Health
FALCON trial of fulvestrant for advanced breast cancer
The Phase III FALCON trial compared fulvestrant to anastrozole for hormone receptor-positive advanced breast cancer.
Brandcast Health
Overview of the GIANT Health Event
Shafi Ahmed, PhD, FRCS, Director of Virtual Medics and Medical and GIANT Event Co-chair, provides an overview of the GIANT Health Event.
Brandcast Health